Genmab — November 2017
-
Tak jky
-
Enig Bibob - det burde det ikke i sig selv og han anbefaler jo også køb på en overreaktion (citat: a significant overreaction). Novod regner iøvrigt med 30 pct rabat i europa sammenlignet med US - og intet på solide eller Tiso - ikke ligefrem en aggressiv tilgang må man sige.
-
at least someone still writing about Ofa in CLL (which seems a lost battle?) https://www.ashclinicalnews.org/online-exclusive/adding-idelalisib-ofatumumab-improves-progression-free-survival-patients-relapsed-cll/
-
Hvis der skulle være tvivl om dara’s plads i myelomatose, så er her et fint overblik over mulighederne i RRMM https://twitter.com/vince
ntrk/status/927611793991782400 -
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind